The Connection between MiR-122 and Lymphocytes in Patients Receiving Treatment for Chronic Hepatitis B Virus Infection

Author:

Manea Marina1ORCID,Apostol Dimitri1,Constantinescu Ileana12

Affiliation:

1. Immunology and Transplant Immunology, University of Medicine and Pharmacy “Carol Davila”, 020021 Bucharest, Romania

2. Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 022328 Bucharest, Romania

Abstract

New molecular predictors for the response to treatment in HBV (hepatitis B virus) infection are assessed. Among them is miR-122. Our article searches the connection between miR-122 and the counts of lymphocytes in chronic HBV patients receiving treatment. We included the sera of 38 Romanian subjects with chronic HBV infection (20 receiving treatment and 18 not receiving treatment) and 5 healthy controls. The expression of miR-122 was determined using RT-PCR (real-time PCR) and a 2−ΔΔCT method. Two systematic analyses were also performed on databases (PUBMED, Web of Science, and Science Direct), eliminating systematic reviews, editorials, letters to editors, meta-analyses, reviews, conference proceedings, or pre-print manuscripts. We included human-based articles following the PRISMA criteria and the Newcastle Ottawa Assessment Scale for Case–Control and Cohort studies. R 4.2.2 was used for statistics, and MIENTURNET and STRING were used for the bioinformatic analysis. Our results showed a link between the variations in the expression of miR-122 and the counts of lymphocytes in HBV Romanian patients receiving therapy. Treatment influenced miR-122 and the lymphocyte numbers. This is the first study with these results, and it may lead to a new perspective on the inter-relationships between microRNAs and therapy in HBV patients.

Publisher

MDPI AG

Subject

Virology,Microbiology (medical),Microbiology

Reference80 articles.

1. World Hepatitis Day 2023 (2023, July 29). Key Messages. Available online: https://www.who.int/campaigns/world-hepatitis-day/2023/key-messages.

2. (2023, July 29). World Hepatitis Day 2023: Need to scale up efforts to address hepatitis B and C. Available online: https://www.ecdc.europa.eu/en/news-events/world-hepatitis-day-2023-need-scale-efforts-address-hepatitis-b-and-c.

3. Centers for Disease Control and Prevention (2023, September 22). Reduce Reported Rate of Hepatitis B-Related Deaths by 20% or More, Available online: https://www.cdc.gov/hepatitis/policy/npr/2023/NationalProgressReport-HepB-ReduceDeaths.htm.

4. (2023, July 29). Viral Hepatitis: A Significant Threat to Health Worldwide. Available online: https://easl.eu/news/whd2023.

5. Sausen, D.G., Shechter, O., Bietsch, W., Shi, Z., Miller, S.M., Gallo, E.S., Dahari, H., and Borenstein, R. (2022). Hepatitis, B.; Hepatitis, D. Viruses: A Comprehensive Update with an Immunological Focus. Int. J. Mol. Sci., 23.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3